A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details.
Fiche du document
- doi: 10.1111/ene.14382
- issn: 1351-5101
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1111/ene.14382
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32503088
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1468-1331
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0FFA857C79C53
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
Complications and sequelae Semiology (Medicine) Diseases--Symptoms Symptomatology Signs, Clinical Clinical signs Semiology Symptomology Signs and symptoms Disease symptoms Cerebrorachidian fluid CSF (Cerebrospinal fluid)Citer ce document
M. Romoli et al., « A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details. », Serveur académique Lausannois, ID : 10.1111/ene.14382
Métriques
Partage / Export
Résumé
We systematically reviewed available evidence for reports of neurological signs and symptoms in patients with COVID-19 to identify cases with severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection or immune-mediated reaction in the nervous system. We followed PRISMA guidelines and used the MEDLINE, EMBASE, Google Scholar, MedRxiv and ChinaXiv databases to search for articles on COVID-19 and nervous system involvement that were published from 1 January to 24 April 2020. Data on design, sample size, neurological assessment and related work-up were extracted. Biases were assessed with the Newcastle-Ottawa scale. We analysed 27 publications on potential neuroinvasive or parainfectious neurological complications of COVID-19. The reports focused on smell and taste (n = 5) and evaluation of neurological symptoms and signs in cohorts (n = 5). There were cases of Guillain-Barré syndrome/Miller-Fisher syndrome/cranial neuropathy (seven cases), meningitis/encephalitis (nine cases) and various other conditions (five cases). The number of patients with examination of cerebrospinal fluid and, in particular, SARS-CoV-2 polymerase chain reaction was negligible. Two had a positive SARS-CoV-2 polymerase chain reaction examination of cerebrospinal fluid specimen. Study of potential parenchymal involvement with magnetic resonance imaging was rare. Only four reports received a rating of the highest quality standards. This systematic review failed to establish comprehensive insights into nervous system manifestations of COVID-19 beyond immune-mediated complications in the aftermath of respiratory symptoms. The authors therefore provide guidance for more careful clinical, diagnostic and epidemiological studies to characterize the manifestations and burden of neurological disease caused by SARS-CoV-2 on behalf of the Infectious Disease Panel of the European Academy of Neurology.
